By Michael D. Privitera MD;Jennifer Cavitt MD;David M. Ficker MD;Jerzy P. Szaflarski MD PhD;Timothy E. Welty PharmD FCCP BCPS;Marcia J. Kaplan MD
Designed for fast point-of-care reference, this guide bargains evidence-based guidance on use of antiepileptic medicines for seizures, psychiatric problems, soreness, and headache. Chapters hide all medicinal drugs, together with the lately licensed drug pregabalin. for every drug, the authors checklist FDA-approved symptoms and summarize the facts for efficacy and tolerability from medical trials for epileptic, psychiatric, discomfort, and headache symptoms. additionally integrated are strategies from specialist societies reminiscent of the yankee Academy of Neurology, American Psychiatric organization, and organization for the research of Headache. Tables within the ultimate bankruptcy summarize those thoughts and point out the authors' collection of drug in numerous medical events.
Read or Download Clinician's Guide to Antiepileptic Drug Use PDF
Best clinical medicine books
Cognitive Behaviour remedy is significantly altering the way in which humans deal with difficulties of their lives and has a profoundly optimistic influence on activity pride for psychological medical experts. The Case research consultant to Cognitive Behaviour treatment of Psychosis is written via practitioners from differing scientific backgrounds and at assorted levels of their use of CBT.
It has lengthy been identified that points of habit run in households; stories convey that features regarding cognition, temperament, and all significant psychiatric issues are heritable. This quantity bargains a primer on figuring out the genetic mechanisms of such inherited qualities. It proposes a suite of tools—a conceptual basis—for significantly comparing fresh reports and provides a survey of effects from the most recent study within the rising fields of cognitive genetics and imaging genetics.
Written and edited through world-renowned leaders within the box! provides new instructions for the prevention and therapy of arterial and venous cardiovascular thrombotic and thromboembolic illnesses. Updates modern considering concerning low-molecular-weight-heparins (LMWH), platelet receptor antagonists, and direct thrombin inhibitors to control acute coronary syndromes.
Whilst is hypnosis introduced into play with a number of theoretical and medical ways to psychotherapy? What does a hypnotherapist truly do on a case-by-case and a session-by-session foundation? What particular thoughts might be carried out? What are the scope and nature of the demanding situations that hypnotherapists and their consumers face?
- Men and Depression: Clinical and Empirical Perspectives
- Clinical Pragmatics
- Molecular Pathology in Clinical Practice
- Child and Family Assessment: Clinical Guidelines for Practitioners (2nd Edition)
Extra info for Clinician's Guide to Antiepileptic Drug Use
Enzyme-inducing drugs (AEDs and rifampin) increase the clearance of lamotrigine. ♦ Minimum effective dose varies by indication and concomitant medication (see the preceding text). ♦ Maximum dose in trials varies by indication and concomitant medication (see the preceding text). References 1. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 1998;51(4):1018â 1025. 2. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy.
Indicated as add-on therapy in children aged 4 to 16 years with focal-onset seizures • ADVERSE EFFECTS ♦ In general, the most frequently reported side effects of oxcarbazepine include fatigue, headache, dizziness, somnolence, ataxia, nausea/vomiting, and diplopia. 1,4,5,6 In both oxcarbazepine versus PHT trials, discontinuation due to side effects (one of the primary outcome measures) was significantly higher in the PHT arm than in the oxcarbazepine arm. 6 ♦ Idiosyncratic. 5% of patients enrolled in the controlled trials (6% of these patients being older than 65 years).
Efficacy, tolerability, and clinical utility (treatment retention) ⋅ Results. There were no differences in seizure freedom in patients receiving oxcarbazepine (300 to 1,350 mg/day) versus those receiving PHT (100 to 400 mg/day) (61% seizure free versus 60% seizure free, respectively). 002). 45 46 ◊ Study Type. RCT2,3 ⋅ Main Entry Criteria. Children and adults with new-onset epilepsy (10 to 69 years) ⋅ Comparator. Placebo ⋅ Number of Patients. 67 ⋅ Primary Outcome Variable. Time to first seizure ⋅ Results.